WATCH LIVE
timothy sykes logo
CRSP Jumps As Morgan Stanley Doubles Price Target Thumbnail
G Google News

CRSP Jumps As Morgan Stanley Doubles Price Target

JACK KELLOGG•UPDATED JUL. 4, 2026, 11:08 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

CRISPR Therapeutics AG stocks have been trading up by 7.62 percent after breakthrough gene-editing trial results energized investors

What Traders Need To Know

  • Morgan Stanley upgraded Crispr Therapeutics AG from Underweight to Equal Weight and lifted its price target from $33 to $60, signaling a clear sentiment shift.
  • The upgrade leans on better visibility around the Casgevy launch and improving revenue recognition prospects, which can reshape revenue expectations.
  • Morgan Stanley also highlighted potential value in CRISPR Therapeutics AG’s in vivo delivery pipeline, putting more focus on longer-term platform optionality.
  • Recent Form 4 filings showed changes in beneficial ownership by an insider or major holder, but with no detail on transaction size, direction, or context.

Candlestick Chart

Weekly Update Jun 29 – Jul 03, 2026: On Saturday, July 04, 2026 CRISPR Therapeutics AG stock [NASDAQ: CRSP] is trending up by 7.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Crispr Therapeutics remains a high‑beta, clinical‑stage gene‑editing pure play with negligible revenue ($1.5M in Q1 2026; 3‑year revenue CAGR sharply negative) and severely loss‑making operations (EBIT margin deeply negative, ROE about -31%). However, the balance sheet is robust: ~$2.4B in cash and investments, current ratio ~18x, modest leverage (total debt/equity ~0.4x). Free cash flow of roughly -$109M in Q1 implies >4 years of runway, supporting ongoing Casgevy commercialization and in vivo pipeline development despite heavy R&D (~$69M in Q1).

Weekly price action from late June to early July shows a sharp rebound from ~$54 to just under $60, confirming a strong short‑term uptrend after the Morgan Stanley upgrade. The rapid move through the mid‑50s, combined with intraday 5‑minute candles showing expanding ranges and elevated volume near $60, signals aggressive momentum buying. Key actionable level is $55–56, now firm support; tactical long entries on pullbacks toward that zone with a stop below $52 target a retest and breakout above $60–62 resistance.

The Morgan Stanley upgrade to Equal Weight with a $60 target validates improving Street conviction around Casgevy launch visibility and the in vivo platform, distinguishing CRSP from broader biotech, where many peers lack approved products or similar optionality. Insider Form 4 activity, absent detail, is noise versus the strategic de‑risking from first commercial revenues and ample cash. Relative to healthcare and biotech benchmarks, risk is higher but so is upside; base case 12‑18 month valuation range is $70–75, with support near $52 and major resistance around $80.

More Breaking News

Quick Financial Overview

CRISPR Therapeutics AG (CRSP) is trading in a zone where sentiment is improving, but the fundamentals still look early stage. The weekly data show the stock holding in the mid-$50s to around $60, with recent closes from roughly $54 to just under $60. That suggests dip buyers are stepping in on retraces toward the low-to-mid $50s, while the $60 area is acting as near-term resistance after the Morgan Stanley upgrade.

Intraday, the 5-minute snapshot shows a strong push from about $56 into the low $60s, a wide intraday range that points to aggressive buying and short-covering. For short-term traders, that kind of range expansion often marks a momentum pivot, but it also raises the risk of sharp pullbacks if the move gets crowded. Price holding above the breakout zone near $56–$57 will be key if CRSP is going to build a sustained trend.

Financially, CRISPR Therapeutics AG is still a high-burn, pre-scale biotech story. Quarterly revenue is tiny at about $1.5M, while net income sits deeply negative near -$123M, and operating cash flow is around -$109M. On the balance sheet, though, cash and short-term investments exceed $2.4B, current ratio is about 18, and total debt to equity is low around 0.43, giving CRSP substantial runway. The trade-off is a steep price-to-sales ratio above 1,200 and heavily negative margins, which means traders are paying for pipeline and future optionality, not current earnings.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”